TABLE 3.
Summary of CC50, EC50, and SI values of the compounds against BIRFLU during cotreatment in MDCK cellsa
| Compound | Activity statistics of compound against BIRFLUb
|
||||
|---|---|---|---|---|---|
| CC50 (MTT) (μM) | CC50 (XTT) | EC50 | SI (MTT) | SI (XTT) | |
| AmA | >50.00 | <2.54 nM | 34.69 nM | >1,441.33 | <0.07 |
| BRQ | >50.00 | >50.00 μM | >50.00 μM | 1.00 | 1.00 |
| 6-Azauridine | 42.66 | >50.00 μM | 7.52 μM | 5.67 | >6.65 |
| Azaribine | 19.66 | >50.00 μM | 3.75 μM | 5.24 | >13.33 |
| PF | 33.35 | >50.00 μM | 2.04 μM | 16.35 | >24.51 |
| AVN-944 | 29.61 | >50.00 μM | 37.78 μM | 0.78 | >1.32 |
| MMF | >50.00 | >50.00 μM | >50.00 μM | 1.00 | 1.00 |
| MPA | >50.00 | >50.00 μM | >50.00 μM | 1.00 | 1.00 |
| Ribavirin | >50.00 | >50.00 μM | >50.00 μM | 1.00 | 1.00 |
a
BIRFLU, A/Puerto Rico/8/34 H1N1.
b
CC50, median 50% cytotoxicity concentration; EC50, median 50% effective concentration; SI, selective index (CC50/EC50).